EUCTR2008-002325-37-DE进行中（未招募）不适用
Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group trial
Department of Medicine I, University Hospital St. Josef-Hospital, Ruhr University Bochum0 个研究点开始时间: 2009年8月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Age between 18 and 75 years, inclusive.
- •(2) Patients present with histologically proven non-alcoholic steatohepatitis ascertained by the single center pathologist between visit 1 and 2
- •(3) First liver biopsy was obtained not later than 6 months before visit 1
- •(4) Patients have HbA1c not exceeding 10.0%.
- •(5) Patients have a history of stable body weight (not varying by >10% for at least 3 months prior to screening).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) Patients are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •(2) Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures include sterilisation, hormonal intrauterine devices, oral contraceptives, sexual abstinence or vasectomised partner.). A male subject who is sexually active and has not been surgically sterilised must be informed that he must either use a condom during intercourse, ensure that his partner practices contraception, or he must refrain from sexual intercourse during the trial and until 1 month after completion of the trial. This is to prevent the possibility of a pregnancy from spermatocytes that can potentially be damaged by trial medication. It is strongly recommended that the female partners use a highly effective contraception (Pearl Index < 1%).
- •(3) Patients have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days prior to screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
- •(4) Patients with evidence of viral or autoimmune hepatitis (positive testing for
- •HBsAG, anti-HCV or anti-HIV, pos. AMA-screen, ANA-titer > 1:160)
- •(5) Patients with inherited liver diseases (e.g. Wilson’s disease, Hemochromatosis)
- •(6) Patients have alcohol consumption (>20 g daily for males and >10 g daily for females)
- •(7) Patients have decompensated liver cirrhosis (Child-Pugh score ?7)
- •(8) Patients have alanine aminotransaminase (ALT) greater than ten times the upper limit of the reference range.
- •(9) Patients have had greater than three episodes of severe hypoglycemia within 6 months prior to screening.
- •(10) Patients are undergoing therapy for a malignancy, other than basal cell or squamous cell skin cancer.
- •(11) Patients have cardiac disease that is Class III or IV, according to the New York Heart Association criteria.
- •(12) Patients have a known allergy or hypersensitivity to exenatide, or excipients contained in these agents.
- •(13) Patients have or had concomitant medication with thiazolidinediones.
- •(14) Patients have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine >1.8 mg/dL for males and greater than or equal to >1.5 mg/dL for females.
- •(15) Patients have known hemoglobinopathy or chronic anemia
- •(16) Patients are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.
- •(17) Patients have used any prescription drug to promote weight loss within 3 months prior to screening.
- •(18) Patients have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes them from following and completing the protocol, in the opinion of the investigator.
- •(19) Patients fail to satisfy the investigator of suitability to participate for any other reason.
研究者
相似试验
已完成
4 期
Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)Nonalcoholic Fatty Liver DiseaseNCT01208649Ruhr University of Bochum13
已完成
3 期
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese SubjectsWeight LossObesityNCT00856609National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)150
已完成
4 期
The Effect of Exenatide on Weight and Hunger in Obese, Healthy WomenImpaired Glucose ToleranceObesityNCT00456885Beth Israel Deaconess Medical Center41
进行中（未招募）
不适用
Effect of additional treatment with exenatide in patients with an acute myocardial infarction: the EXAMI trial)EUCTR2009-014272-21-NLVU University Medical Center40
进行中（未招募）
1 期
Exenatide Treatment in Parkinson's DiseaseParkinson's diseaseEUCTR2019-000732-26-SEStockholm Health Care Services60